Affordable Access

deepdyve-link
Publisher Website

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.

Authors
  • Jeyakumar, Ghayathri1
  • Kim, Seongho2
  • Bumma, Naresh1
  • Landry, Craig1
  • Silski, Cynthia1
  • Suisham, Stacey1
  • Dickow, Brenda1
  • Heath, Elisabeth1
  • Fontana, Joseph1
  • Vaishampayan, Ulka3
  • 1 Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4 HWCRC 4100 John R, Detroit, MI, 48201, USA.
  • 2 Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA.
  • 3 Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4 HWCRC 4100 John R, Detroit, MI, 48201, USA. [email protected]
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Oct 17, 2017
Volume
5
Issue
1
Pages
82–82
Identifiers
DOI: 10.1186/s40425-017-0287-5
PMID: 29041991
Source
Medline
Keywords
License
Unknown

Abstract

Pretherapy NLR <3 and duration of prior anti-VEGF therapy of <6 months, are independent statistically significant predictors of longer PFS and OS with ICI therapy in mRCC. Validation is required in a larger sample size with multi-institutional collaboration.

Report this publication

Statistics

Seen <100 times